ENGLEWOOD, Colo., April 3, 2024 /PRNewswire/ -- Ampio
Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or
"Ampio") today announced that, as previously disclosed in its
Annual Report on Form 10-K for the year ended December 31, 2023, which was filed on
March 27, 2024 with the Securities
and Exchange Commission, the audited financial statements contained
an unqualified audit opinion from its independent registered public
accounting firm that included an explanatory paragraph related to
the Company's ability to continue as a going concern. Further
discussion is included in footnote 2 of the Company's financial
statements included in the Company's Annual Report on Form 10-K.
This announcement is made pursuant to NYSE American LLC Company
Guide Section 610(b), which requires public announcement of the
receipt of an audit opinion containing a going concern paragraph.
This announcement does not represent any change or amendment to the
Company's financial statements or to its Annual Report on Form 10-K
for the year ended December 31,
2023.
For more information, contact:
Ampio Pharmaceuticals,
Inc.
Michael A. Martino
Chief Executive Officer
mmartino@ampiopharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ampio-pharmaceuticals-received-audit-opinion-with-going-concern-explanation-302107593.html
SOURCE Ampio Pharmaceuticals, Inc.